Harmon Cyrus
SEC CIK 1831410 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| OLMA | Olema Pharmaceuticals, Inc. | Dir | 702.8K | — | $6.22M | 33 | 2021-07-19 | 2026-07-23 |
Most active insiders at OLMA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | CLARK IAN T | Dir | — | $7.87M |
| 2 | Zojwalla Naseem | Chief Medical Off | — | $7.53M |
| 3 | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | — | $4.66M |
| 4 | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | — | $2.98M |
| 5 | Mitchell Shawnte | CLO | — | $951.5K |
| 6 | Harmon Cyrus | Dir | — | $743.8K |
| 7 | Austin Sasha Lu | VP of Fin, Ctrl | — | — |
| 8 | Bohen Sean | Pres, CEO, Dir | — | — |
| 9 | RAPPAPORT ANDREW | Dir | — | — |
Transactions 33
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-07-27 19:30 | 2026-07-23+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $11.65 | -25.0K | 702.8K | -3% | -$291.2K |
| 2026-01-21 | 2026-01-20 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $26.88 | -10.0K | 727.8K | -1% | -$268.8K | |
| 2026-01-16 | 2026-01-14 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $29.12 | -3,489 | 737.8K | -0.5% | -$101.6K | |
| 2025-12-29 | 2025-12-22 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $28.53 | -2,881 | 741.3K | -0.4% | -$82.2K | |
| M | 2025-09-18 | 2025-09-16+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $8.19 | -20.0K | 744.1K | -3% | -$163.7K |
| MI | 2025-09-18 | 2025-09-16+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $8.23 | -5,000 | 120.1K | -4% | -$41.1K |
| 2024-12-11 | 2024-12-09 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | A - Grant | $0.00 | +29.2K | 780.5K | +4% | $0 | |
| M | 2024-12-11 | 2024-12-10+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $9.03 | -16.4K | 764.1K | -2% | -$148.0K |
| M | 2024-07-31 | 2024-07-29+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $15.57 | -5,000 | 751.3K | -0.7% | -$77.9K |
| 2024-07-12 | 2024-07-11 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $12.26 | -5,000 | 756.3K | -0.7% | -$61.3K | |
| 2024-07-02 | 2024-06-28 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $10.77 | -20.0K | 761.3K | -3% | -$215.4K | |
| M | 2024-06-04 | 2024-05-31+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $10.30 | -25.0K | 786.3K | -3% | -$257.4K |
| 2024-05-07 | 2024-05-06 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $10.92 | -5,000 | 806.3K | -0.6% | -$54.6K | |
| 2024-05-02 | 2024-04-30 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $9.51 | -15.0K | 811.3K | -2% | -$142.7K | |
| 2024-03-29 | 2024-03-28 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $10.97 | -20.0K | 826.3K | -2% | -$219.4K | |
| M | 2024-03-04 | 2024-02-29 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $12.41 | -25.0K | 846.3K | -3% | -$310.3K |
| M | 2024-02-02 | 2024-01-31+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $12.79 | -30.0K | 871.3K | -3% | -$383.6K |
| M | 2024-01-02 | 2023-12-29 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $13.38 | -25.0K | 903.8K | -3% | -$334.5K |
| 2023-12-01 | 2023-11-30 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $12.57 | -25.0K | 926.3K | -3% | -$314.2K | |
| 2023-11-22 | 2023-11-20 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | A - Grant | $0.00 | +15.8K | 959.5K | +2% | $0 | |
| M | 2023-11-22 | 2023-11-21+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $14.39 | -8,181 | 951.3K | -0.9% | -$117.7K |
| M | 2023-11-02 | 2023-10-31+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $12.65 | -30.0K | 943.7K | -3% | -$379.4K |
| 2023-10-03 | 2023-09-29 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $12.41 | -25.0K | 973.7K | -3% | -$310.2K | |
| A | 2023-09-05 | 2023-08-16 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $10.14 | -15.0K | 1.02M | -1% | -$152.1K |
| M | 2023-09-05 | 2023-08-31+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $10.26 | -25.0K | 998.7K | -2% | -$256.6K |
| 2023-08-17 | 2023-08-16 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $10.14 | -15.0K | 1.02M | -1% | -$152.1K | |
| 2023-06-09 | 2023-06-08 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $6.30 | -10.0K | 1.04M | -1.0% | -$63.0K | |
| M | 2023-06-07 | 2023-06-05+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $6.17 | -10.0K | 1.05M | -0.9% | -$61.8K |
| 2021-12-01 | 2021-11-29 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | CTO, Dir | S - Sale | $24.76 | -400 | 1.05M | -0.0% | -$9,904 | |
| M | 2021-10-21 | 2021-10-19 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | CTO, Dir | S - Sale | $27.98 | -12.0K | 1.05M | -1% | -$335.8K |
| 2021-09-21 | 2021-09-20 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | CTO, Dir | S - Sale | $26.30 | -12.0K | 1.06M | -1% | -$315.6K | |
| 2021-08-20 | 2021-08-19 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | CTO, Dir | S - Sale | $24.97 | -12.0K | 1.08M | -1% | -$299.6K | |
| M | 2021-07-21 | 2021-07-19+ | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | CTO, Dir | S - Sale | $25.10 | -12.0K | 1.09M | -1% | -$301.3K |
Purchase Sale Sale after option exercise All abbreviations